Structure of a kinase-bound inhibitor of melanoma growth and invasiveness

Ronen Marmorstein group (Wistar Institute)


Ronen Marmorstein's group at the Wistar Institute published an exciting advance towards anti-cancer therapy. The authors described an approach of using structure-based design to develop a novel class of potent organoruthenium inhibitors that displayed excellent selectivity in vitro to phosphatidyl-inositol-3-kinase (PI3K) over a range of other representative protein kinases. The most potent inhibitor was found to potently and specifically inhibit the PI3K signaling pathway in a melanoma cell line, and it was also found to strongly inhibit human melanoma growth and invasiveness. The crystal structure solved from the data collected at GM/CA-CAT beamline 23ID-D helped to elucidate the structural features that contribute to the high specificity of this novel class of organoruthenium inhibitors to PI3K. In addition, the structural evidence provides a potential means to design of organometallic PI3K inhibitors that possess specificity towards different PI3K isoforms.

Figure: The structure of the E5E2 inhibitor bound to PI3K (green), is overlaid with three other protein kinases (blue, yellow, pink).


Xie, P, Williams, DS, Atilla-Gokcumen, GE, Milk, L, Xiao, M, Smalley, KSM, Herlyn, M, Meggers, E, Marmorstein, R. Structure-Based Design of an Organoruthenium Phosphatidyl-inositol-3-kinase Inhibitor Reveals a Switch Governing Lipid Kinase Potency and Selectivity, Chem. Biol. 3 (5), 305-316 (2008). DOI: 10.1021/cb800039y



GM/CA @ APS Sponsors: National Institute of General Medical Sciences (NIGMS) and National Cancer Institute (NCI) of the National Institutes of Health (NIH).

  GM/CA @ APS is an Office of Science User Facility operated for the U.S. Department of Energy by Argonne National Laboratory

  UChicago Argonne LLC | Privacy & Security Notice | Contact Us | A-Z Index | Search